Articles tagged with Immunotherapy
Researchers have developed a novel synthetic ligand using AI-based computational protein design, activating the Notch signaling pathway in T-cells. This breakthrough enables broadened clinical T-cell production and advances immunotherapy development.
A study of ovarian tumor immune landscapes reveals four distinct immunologic subtypes, with those with T cells surviving longer and having better outcomes. The researchers also found that myeloid cells play a key role in reestablishing the immune landscape upon recurrence.
A recent study identified four genes associated with treatment resistance to immunotherapy in melanoma patients. The genes, CD24, NFIL3, FN1, and KLRK1, were found to be linked to mechanisms of immune evasion and suppression of the inflammatory response. Patients with high expression of these genes had significantly lower overall survi...
Researchers discovered that a type of HPV commonly found on the skin can directly cause a form of skin cancer called cutaneous squamous cell carcinoma when immune cells malfunction. The study's findings suggest that other people with defective T-cell responses may also be susceptible to cancer caused directly by beta-HPV.
A new study shows that delivering a single injection of gene therapy at birth may offer years-long protection against HIV. The treatment uses an adeno-associated virus to deliver instructions to muscle cells, which produce broadly neutralizing antibodies capable of neutralizing multiple strains of HIV.
This meta-analysis found that FMT combined with ICIs resulted in improved objective response and disease control rates, with an acceptable safety profile. Subgroup analysis revealed a significant association between the combination of anti-PD-1 and anti-CTLA-4 therapies and higher overall response rates.
A decade-long study reveals that the source of dietary fat, not adiposity itself, is the primary factor influencing tumor growth in obese mice. High-fat diets derived from animal fats compromise anti-tumor immunity and accelerate tumor growth, while plant-based fats have a neutral effect.
Researchers discovered a way to boost T cells' ability to fight cancer by rewiring their energy metabolism. By blocking Ant2 protein, they created a state of heightened readiness and potency in T cells, leading to greater stamina, faster replication, and sharper targeting of cancerous threats.
Researchers at UC San Diego School of Medicine have developed a novel approach to enhance the effectiveness of immunotherapy treatments for head and neck squamous cell carcinomas (HNSCC). Delivering radiation therapy that preserves tumor-draining lymph nodes followed by immunotherapy resulted in a complete and durable tumor response in...
Researchers propose a synergistic combination strategy using systemic type I interferons (IFN-I) and local TLR7/8 agonists to enhance dendritic cell activation and inhibit metastatic tumors. This approach enhances early innate immune control and later induces CD8+ T cell responses.
Diana Hargreaves will receive $1 million to advance her project on improving immunotherapy in patients with pancreatic cancer. Her previous work identified better drug targets for cancers with SWI/SNF mutations, leading to breakthroughs in treating difficult-to-treat cancers.
Researchers identified key factors behind a successful immunotherapy response in a young patient with rhabdoid tumour. The study highlights the potential of sequencing technologies to track immune cell profiles and develops personalized cell therapies.
Researchers at MD Anderson identified specific co-mutations in KRAS-mutant non-small cell lung cancer (NSCLC) that improve treatment response to ATR inhibitors. Additionally, chemotherapy was found to drive changes to the genome and clonal architecture of blood stem cells, increasing the risk of secondary malignancies.
Researchers from Korea University have discovered that the protein WEE1 can paradoxically drive immune resistance in cancer cells when located in the cytoplasm. This study suggests that targeting WEE1 with an inhibitor, such as adavosertib, may sensitize tumors to immunotherapy and reinvigorate antitumor immunity.
Researchers from Memorial Sloan Kettering Cancer Center developed a new approach to induce mutations in resistant cancer cells, making them sensitive to immunotherapy. The study showed positive outcomes in patients over 90 with lung cancer who underwent surgery.
A Phase II study found that 87% of patients with stage III melanoma remained alive and disease-free four years after treatment with nivolumab and relatlimab. Researchers identified unique biomarkers associated with better outcomes, including high TIGIT levels and low B7-H3 levels.
A retrospective study found teclistamab-cqyv to be effective in patients with high-risk, heavily pretreated multiple myeloma who would have been ineligible for the MajesTEC-1 trial. The bispecific antibody reduced disease burden by at least half in 53% of evaluable patients, and 45% achieved a 'very good partial response'. Despite a hi...
A new study from the University of Pittsburgh shows exercise improves cancer outcomes and enhances response to immunotherapy in mice by reshaping the gut microbiome. The research found that a specific compound called formate, produced by gut bacteria in exercised mice, was associated with better outcomes in patients with melanoma.
A new dual CAR-T cell therapy has been developed to target T-ALL, showing high efficacy and safety. The treatment targets two antigens simultaneously, making it more effective than previous therapies. Experimental results demonstrate its ability to control the disease in both laboratory and animal models, with an excellent safety profile.
CD8⁺ T cell exhaustion is the silent saboteur of immune destruction, caused by chronic antigen exposure, immune suppressor cells, and epigenetic shifts. Next-generation interventions like CAR-T engineering and CRISPR-based reprogramming promise to restore immune vigor.
Researchers develop self-assembling nanoparticles that induce ferroptosis in bladder cancer cells while reprogramming the tumor immune microenvironment, boosting anti-tumor activity. The nanomedicine has dual functions as a multifaceted approach to overcome treatment resistance and is Clinically translatable.
Researchers have discovered that blocking NK cell checkpoints could significantly enhance cancer immunotherapy, providing new avenues for treating solid tumors and blood cancers. Emerging precision approaches using gene editing and engineered cell therapies promise specific recognition of cancer cells with potentially fewer side effects.
A new dual-phase CT AI tool, NeoPred, combines pre-treatment and pre-surgery scans with clinical data to predict major pathological response in NSCLC patients. The model achieved high accuracy rates, including AUCs of 0.772-0.787, outperforming surgeons and improving diagnostic accuracy.
Researchers at MD Anderson have made significant breakthroughs in cancer treatment, including improved outcomes for elderly patients with IDH-mutant AML who are not eligible for intensive chemotherapy. Additionally, new targeted therapies have been approved as frontline treatments, while pre-surgical radiation therapy may offer an alte...
The BRACELET-1 trial demonstrated a 20% objective response rate and 12.1-month progression-free survival for patients with unresectable HR+ HER2- tumors, suggesting that adding pelareorep to paclitaxel chemotherapy warrants further investigation in metastatic breast cancer.
A new review identifies CHEK2 as a potential biomarker for predicting response to immunotherapy and suggests that combining CHEK2 inhibitors with existing therapies may enhance anti-tumor effects. This could lead to improved treatment outcomes in solid tumors.
The addition of perioperative toripalimab to platinum-based chemotherapy has demonstrated significant improvements in disease-related outcomes, including event-free survival and major pathologic response rates. However, this is associated with a small increase in grade 3–5 toxicities and immune-related adverse events.
Researchers at MD Anderson have made significant progress in treating non-small cell lung cancer (NSCLC) by combining chemotherapy, immunotherapy, and surgery. They found that pre-surgical combination therapy showed promising results, with high rates of pathological complete response and major pathological response.
Researchers found that using Tumor Treating Fields therapy (TTFields) combined with immunotherapy (pembrolizumab) and chemotherapy (temozolomide) may extend survival for glioblastoma patients. TTFields disrupt tumor growth, attracting more immune cells to attack cancerous cells.
Researchers identified a link between the loss of Y chromosome in white blood cells and reduced ability to kill cancer cells. This finding may explain why men with loss of Y have higher cancer risks and poorer outcomes. The study provides insights into how this genetic change affects immune system function.
The study identified key proteins and signaling pathways involved in CAR-T cell therapy's efficacy, including cytokines, kinases, receptors, proteases, and chemical messengers. The findings pave the way for new treatment advances and potential biomarkers.
A phase 2 trial found that combining avelumab and cetuximab significantly extended median progression-free survival in patients with advanced cutaneous squamous cell carcinoma. The combination showed synergistic effects, suggesting a potential new standard of care for this patient population.
Dr. Natalie Artzi joins the Wyss Institute as Associate Institute Director, working closely with Don Ingber to shape strategic direction and advance research and translation efforts. She leads a world-class research program focused on developing tissue- and cell-responsive nanostructures for disease tracking and treatment.
Researchers at Memorial Sloan Kettering Cancer Center have discovered that Bacillus Calmette-Guérin (BCG) therapy reprograms and amplifies cells in the bone marrow, enhancing the innate immune system's ability to combat cancer. This breakthrough could lead to improved immunotherapies for various cancers.
Researchers have uncovered a key reason why HIV remains difficult to cure, revealing that subtle variations in the Rev-RRE axis influence viral replication and latency reactivation. Understanding this regulatory system could help develop strategies to flush out the dormant virus and eliminate it for good.
Researchers developed a dual action immunotherapy using CAR-T cells targeting CD19 and CD22 proteins in B-ALL cancer cells, increasing the efficacy of treatment and reducing relapse rates.
Tumors exploit lipid metabolism to evade immune surveillance and manipulate the tumor microenvironment. Lipid metabolism-related molecules serve as potential biomarkers for early cancer detection and guide diagnosis, prognosis, and treatment decisions.
Researchers identified five adenosine phosphate signaling subtypes in melanoma, associated with immune activation and improved response to anti-PD-1/PD-L1 therapy. The Adenosine Phosphate Signaling Model predicts prognosis and immunotherapy outcomes, offering new biomarker and therapeutic strategies for solid tumors.
A study investigated immune-related adverse events (irAEs) in Latin American patients with advanced liver cancer treated with atezolizumab and bevacizumab. Most irAEs were mild or moderate and resolved within a month, without impacting overall survival.
The University of Texas MD Anderson Cancer Center has been awarded $21.4 million by CPRIT to support cancer research efforts and faculty recruitment. The institution is grateful for the continued funding, which will help advance future potential breakthroughs in cancer treatment.
Researchers review clinical and scientific advances combining radiation therapy with immunotherapy to strengthen the immune response and improve disease control. The approach may offer new treatment options for patients facing hard-to-treat forms of bladder cancer.
A UCLA study found that selective serotonin reuptake inhibitors (SSRIs) can significantly enhance the ability of T cells to fight cancer and suppress tumor growth across various cancer types in mouse and human tumor models. SSRIs increased access to serotonin signals, making killer T cells happier and more effective at killing cancer c...
A new technique using focused sound waves and microbubbles has shown great promise in treating debilitating brain lesions called cerebral cavernous malformations. The approach has halted the growth of lesions almost entirely, offering a potential paradigm shift in treatment.
A new review article reveals the dynamic mechanisms of ROS regulating antigen processing and presentation, proposing combined immunotherapy strategies based on redox homeostasis regulation. Targeting redox homeostasis is a promising direction for enhancing tumor immunotherapy efficacy.
Researchers discovered that ascites fluid produced by ovarian cancer suppresses cytotoxic lymphocytes, crippling immune cells' ability to kill cancer cells. Fats in ascites cripple NK cells, T cells, and innate T cells, which are attractive candidates for cellular immunotherapies.
Researchers found that phospholipids in ascites fluid disrupt immune cell function, particularly NK cells, leading to impaired anti-tumor activity. Blocking these lipids can restore NK cell activity, providing a promising therapeutic target.
Moffitt researchers identified a link between immune cell longevity and tumor antigen stability in patients unresponsive to TIL therapy. This knowledge may lead to improved treatment strategies using gene editing and reintroducing missing antigens.
The ESMO Breast Cancer 2025 congress will cover topics such as circulating tumour DNA, immunotherapies, and emerging therapies for managing breast cancer. The event will feature key findings on predictive biomarkers, ctDNA, and tumour-infiltrating lymphocytes.
Researchers have developed a new approach to improve CAR-T cell therapy effectiveness in treating B-cell Acute Lymphoblastic Leukemia. By creating a TIM-3 decoy, they aim to prevent the tumor from turning off the CAR-T cells, leading to improved anti-leukaemia effectiveness and long-term persistence.
The study of 19,000 patients shows immune checkpoint inhibitors greatly improved survival rates for those living with MSI-H colorectal cancer. Researchers found factors that may improve therapy's effectiveness against MSS tumors under certain conditions.
A review concludes that exposing preschool-aged children to small amounts of food allergens is safer than avoiding them, reducing the risk of severe reactions. Delaying exposure can prolong unnecessary dietary restrictions and increase anxiety related to food allergies.
A new study finds that dexamethasone, a commonly prescribed anti-swelling drug, can significantly reduce the body's immune response to brain cancer for weeks after its last dose. This effect is stronger with higher dosages and may impact immunotherapy treatments.
Researchers have discovered double negative memory B cells, a novel subset of immune cells that are more dysfunctional when in close contact with tumors. These cells may be a useful diagnostic marker and a potential target for developing new immunotherapies.
Researchers found that radiation combined with immune checkpoint inhibitors durvalumab and tremelimumab resulted in durable responses allowing for bladder preservation in localized MIBC patients. The study showed a high efficacy rate of 93% complete response rate, with 84% overall survival rate after two years.
Researchers at Osaka University developed a new technique called single-cell suppressive profiling of regulatory T cells (scSPOT) that can pinpoint the effects of Tregs on all other immune cells. The study found that Tregs most strongly affect CD8-EM T cells, which play a key role in fighting cancer and infections.
A new study led by researchers at Mount Sinai Hospital found that children with high-threshold peanut allergy can be treated with a safe and effective approach, allowing them to tolerate larger doses of peanut butter. The treatment involves gradually increasing doses over 18 months, resulting in sustained unresponsiveness to peanuts fo...
The Micro Immune Response On chip (MIRO) replicates tumours and their environment, allowing researchers to study the efficacy of immunotherapy treatments. This technology has been tested with breast cancer samples and shows promise in understanding how the immune system interacts with tumours.
Researchers at the University of Melbourne have identified a rare type of immune cell, called stem-like T cells, that holds the key to maintaining powerful, long-term immune responses. ID3+ T cells have the remarkable ability to resist burnout and maintain a powerful immune response over time.
A new study published in Nature reveals that tissue-resident memory CD8 T cells play unique roles based on their location within the small intestine, providing a local first line of defense against re-infection. The findings provide insight into how microenvironments and cellular interactions shape immune responses.
A new study published in Oncotarget discovered an anti-correlation between PD-1 and KLRG1 expression in human tumor infiltrating CD8 T cells. This finding suggests the potential for combination therapy to enhance cancer treatment by targeting both markers simultaneously, which could lead to more significant and long-lasting benefits.